On August 25, 2021, Servier Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved ivosidenib for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test.
Read the FDA announcement.
Read Servier Pharmaceuticals' announcement.
Posted 8/26/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
